Corvus Pharmaceuticals

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes immuno-oncology therapies for cancer and immune diseases. The company was incorporated on January 27, 2014, by a team of seasoned biotechnology executives: Richard A. Miller, Joseph J. Buggy, Peter A. Thompson, and Erik Verner. The founders brought extensive experience from previous ventures, notably Pharmacyclics, which was acquired by AbbVie. Dr. Miller, the President and CEO, has a significant track record, having co-founded IDEC (now Biogen) and led research that resulted in the development of Rituxan. He also co-founded and was CEO of Pharmacyclics, where he directed the initial discovery of Ibrutinib.

The company's business is centered on advancing its pipeline of investigational medicines through various stages of clinical development to gain regulatory approval. Its revenue model is predicated on the successful commercialization of these therapies, either independently or through strategic partnerships. Corvus went public with an initial public offering (IPO) on March 23, 2016, listing on the NASDAQ under the ticker symbol CRVS. The company's operations are financed through public offerings and the exercising of stock warrants. A key part of its strategy involves collaboration, such as its partnership with Angel Pharmaceuticals to develop and commercialize its pipeline in greater China.

Corvus's lead product candidate is Soquelitinib, a first-in-class, oral therapy that selectively inhibits ITK (interleukin-2 inducible T-cell kinase) to modulate the immune system. Soquelitinib is currently in a Phase 3 clinical trial for treating peripheral T cell lymphoma (PTCL) and a Phase 2 trial for autoimmune lymphoproliferative syndrome (ALPS). It has also shown promising results in early-stage trials for atopic dermatitis. Other significant candidates in its pipeline include Ciforadenant, an antagonist of the A2A receptor for metastatic renal cell cancer, and Mupadolimab, an anti-CD73 monoclonal antibody. By focusing on precisely targeted therapies, Corvus aims to address unmet medical needs in oncology and immunology, with a mechanism that modulates T-cell and B-cell pathways.